Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;53(2):360-361.
doi: 10.1111/apt.16179.

Letter: propensity score-handle with care

Fabio Salvatore Macaluso  1 , Ambrogio Orlando  1
Affiliations
Comment

Letter: propensity score-handle with care

Fabio Salvatore Macaluso et al. Aliment Pharmacol Ther. 2021 Jan.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51:948-957.
    1. Biemans VBC, van der Woude CJ, Dijkstra G, et al. Dutch initiative on Crohn and Colitis (ICC). Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52:123-134.
    1. Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease. Aliment Pharmacol Ther. 2020;52:1341-1352.
    1. Yao XI, Wang X, Speicher PJ, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst. 2017;109:djw323.
    1. Liu K, Cai F, Huang J. Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth? Aliment Pharmacol Ther. 2020;52:1253-1254.

LinkOut - more resources